Supplementary Method 1. ImageJ macro for quantification of DNA synthesis assay.

Title = getTitle(); Title = replace(Title, ".tif", ""); run("Stack to Images"); rename ("lectin-"+Title); selectWindow(Title+"-0001"); rename ("edu-"+Title); run("Enhance Local Contrast (CLAHE)", "blocksize=9 histogram=256 maximum=3 mask=*None*"); run("Enhance Local Contrast (CLAHE)", "blocksize=9 histogram=256 maximum=3 mask=*None*"); run("Subtract Background...", "rolling=1"); setAutoThreshold("Default dark"); //run("Threshold..."); setThreshold(3000, 65535); run("Convert to Mask"); selectWindow("lectin-"+Title); run("Subtract Background...", "rolling=15"); setAutoThreshold("Default dark"); //run("Threshold..."); setThreshold(400, 65535); run("Convert to Mask"); run("Fill Holes"); run("Watershed"); run("Analyze Particles...", "size=50-Infinity circularity=0.50-1.00 show=[Count Masks] display clear summarize in situ"): setAutoThreshold("Default dark"); //run("Threshold..."); setThreshold(0, 0); run("Create Selection"); selectWindow("edu-"+Title); run("Restore Selection"); run("Clear", "slice"); run("Select None"); run("Analyze Particles...", "size=3-Infinity circularity=0-1.00 show=Outlines display clear summarize in situ");

Supplementary Method 2. ImageJ macro for quantification of DMC1 in the asexual to

sexual conversion assay.

Title = getTitle(); Title = replace(Title, ".tif", ""); run("Stack to Images"); rename ("nuc-"+Title); run("Subtract Background...", "rolling=15"); run("Unsharp Mask...", "radius=3 mask=0.70"); //run("Threshold..."); setAutoThreshold("Huang dark"); run("Convert to Mask"); run("Watershed"); run("Analyze Particles...", "size=40-Infinity show=Outlines display clear summarize in situ"); selectWindow(Title+"-0002"); rename ("lectin-"+Title); selectWindow(Title+"-0001"); rename ("dmc1-"+Title); run("Subtract Background...", "rolling=1"); setAutoThreshold("Huang dark"); //run("Threshold..."); setThreshold(373, 16383); run("Convert to Mask"); run("Fill Holes"); run("Watershed"); selectWindow("lectin-"+Title); run("Subtract Background...", "rolling=1"); setAutoThreshold("Huang dark"); //run("Threshold..."); setThreshold(1300, 16383); run("Convert to Mask"): run("Fill Holes"); run("Watershed"); run("Analyze Particles...", "size=2-50 circularity=0.06-1.00 show=[Count Masks] display clear summarize in situ"); setAutoThreshold("Huang dark"); //run("Threshold..."); setThreshold(0, 0); run("Create Selection"): selectWindow("dmc1-"+Title); run("Restore Selection"); run("Clear", "slice"); run("Select None"); run("Analyze Particles...", "size=0-Infinity circularity=0.5-1.00 show=Outlines display clear summarize in situ");

run("Images to Stack", "name=[] title=[] use");

Supplementary Method 3. Code used for clustering analysis using R studio.

#For generating Dendrograms

####### Relevent Packages and Working Directory ######
setwd("WORKING DIRECTORY") #working directory
library(xlsx) #Importing relevant libraries
library(magrittr)
library(graphics)
library(pvclust)

####### Data Import ######

comp_df<-data.frame(read.xlsx("FILE NAME.xlsx", sheetName = "Sheet1", header = TRUE, rowIndex = c(3:42), colIndex =

c(2:9)))

names(comp_df)<-c("Name","Lab Code", "Mechanism", "ID", "Invasion", "DNAsyn", "Motility", "SexDiff")

####### Data Cleaning ######

##Preparing Data for Dendrograms

char_list<-vector(mode = "integer", length = 33) #Empty vector to hold count values letter_list<-c("A","B","C","D","E","F","G","H","I","J","K", "L","M","N","O","P","Q","R","S","T","U","V", "W", "X", "Y", "Z", "AA", "AB", "AC", "AD", "AE", "AF", "AG") #Possible Groups, this needs additions if more groups emerge for(x in comp_df[,3]){ #Counting group ID occurances char_list[which(x == letter_list)] <- char_list[which(x == letter_list)] + 1 }

repeated_values<- letter_list[which(char_list > 1)] #List of repeated groups

i<-1 for(y in comp_df[,3]){ #IDs compounds belonging to a group

if (y %in% repeated_values){
 comp_df[i,9]<-which(as.character(repeated_values) == as.character(y))</pre>

```
}else{
    comp_df[i,9]<-0
}
i <- i + 1
}</pre>
```

Graphs Generation

```
labelColors = c("#0000FF", "#FF3030", "#228B22", "#D15FEE", "#00CED1", "#8B7355", "#E67732", "#AD00FA", "#FEFF0E" ) #blue, red, green, orchid, turquoise, brown, purple, bright yellow
```

```
colLab <<- function(n) { #Function for coloring labels and assigning compund names as
labels
if(is.leaf(n)) {
    a <- attributes(n)
    attr(n, "nodePar") <-c(a$nodePar, list(lab.col = labelColors[which(repeated_values ==
    as.character(comp_df[a$label,3]))], lab.font = 2))
    attr(n, "label") <- as.character(comp_df[a$label,1])
    }
    n
}</pre>
```

```
cluster_counts<- c(2,3,4,5,6,7) #Number of Clusters
```

```
clust_df=dist(comp_df[,c(5:8)], method = "euclidean") #distance matrix with euclidean values
```

```
dendro_df<-hclust(clust_df,method = "ward.D2")%>% as.dendrogram()
```

```
####### Scaling Data Frames #########
```

```
comp_mean<-apply(na.omit(comp_df[5:8]), 2, mean)
comp_sd<-apply(na.omit(comp_df[5:8]), 2, sd)
comp_max<-apply(na.omit(comp_df[5:8]), 2, max)
comp_min<-apply(na.omit(comp_df[5:8]), 2, min)
comp_mad<-apply(na.omit(comp_df[5:8]), 2, mad)</pre>
```

```
comp_df_scaled<-data.frame(scale(na.omit(comp_df[5:8]), center = comp_mean, scale =
comp_sd))
comp_df_scaled<-cbind(na.omit(comp_df[which(!is.na(comp_df$DNAsyn)),1]),
comp_df_scaled)</pre>
```

```
clust_scaled_dist<-dist(comp_df_scaled, method = "euclidean")</pre>
```

dendro_scaled_dist<-hclust(clust_scaled_dist, method = "ward.D2") %>% as.dendrogram()

par(mar = c(4, 4, 4, 4)) #margins

```
comp_df_scaled_rowNames<-comp_df_scaled
row.names(comp_df_scaled_rowNames)<-comp_df_scaled_rowNames[,1]</pre>
```

PVCLUST Package Developed by Ryota Suzuki(a) and Hidetoshi Shimodaira(b)

a) Ef-prime, Inc.

b) Graduate School of Informatics, Kyoto University









Wiskostatin

Nitazoxanide

Paromomycin

A-2 (MMV665814)



A-5 (MMV666080)



A-6 (MMV000760)



B-1 (MMV006169)



B-5







B-23 (DBeQ)



C-1 (MMV403679)







D-1 (MMV665917)





D-28





MMV665941 (Gentian violet)



MMV665909



MMV001246



Floxuridine

Cladosporin







Clofazimine



OH OH OF

Atorvastatin

Nilotinib

Halofuginone

Oryzalin









BKI-1369

Pyrvinium pamoate

OCH

BKI-1294

BKI-1553



Torkinib



UW2093





Tegaserod maleate

AN6426



Supplementary Figure 1: Test set of compounds used for these studies. In cases where commercially available analogs were purchased (e.g. of compounds from the MMV Malaria Box), lab letter-based codes were established for each compound series. For compounds provided by collaborators, the unique identifiers are given. All of these compounds have previously been publically disclosed.

Supplementary Table 1. Examples of how several inhibitors group according to phenotypic assay results.

| Scaffold class | Compound ID | Sporozoite invasion | DNA synthesis | Parasitophorous vacuole ratio (19.5 hour/6 hour) |
|----------------|-------------|------------------------|---------------|--|
| | B-1 | yes | no | 1.58 |
| 2,4-diamino | B-5 | yes | no | 1.49 |
| quinazolines | B-13 | yes | no | 1.42 |
| | B-23 | yes | no | 1.55 |
| | A-2 | no | yes | 0.69 |
| Quinolinols | A-5 | no | yes | 0.32 |
| | A-6 | no | yes | 0.79 |
| | Floxuridine | no | no | 0.74 |
| | Tegaserod | no | no | 1.01 |

Supplementary Table 2: Compiled assay data for all compounds. Data were generated using compounds at the EC₈₅ for the saxwal growth assay. Each data point represents the mean of at least 2 independent experiments.

| | | Assigned | | | | | | | |
|--|------|-------------------|--------------------|------------|-----------|----------|-----------|------------|--|
| | | hased on | | | | | AGE | axual to | Previously published |
| | | nutative Regu | lar 3 | | | egress | and ser | lieun | information on |
| | | mechanism to 48 | h I | invasion E | DNA | reinvas | sion diff | erentiati | mechanism of action |
| | | or chemical assa | (in a | assay s | synthesis | (mean l | PV on | (mean 9 | ₂ and phenotypic |
| | Lab | relatedness vitro | EC _{eo} (| mean % (| mean % | ratios (| 19.5 inh | ibition of | , effects, and |
| Compound ID | Code | (µM) | | (1000001) | (nodiann) | r(6 h)) | DN | (C1) | naturanes. |
| 2,4-diaminoquinazoline B-1 (MMV006169) | B-1 | D 2.27 | | 56.43 | -31.43 | 8 | 1.58 | 18.08 | C parsum growth inhibitor; unknown mechanism (Besself, et al. 2014. AAC.) |
| 2,4-diaminoquinazoline B-13 | B-13 | D 1.39 | | 82.51 | -3.46 | 8 | 1.42 | 11.26 | 4 B-1 analog: unknown mechanism (Bessoff, et al. 2014. AAC.) |
| 2,4-diaminoquinazoline B-23 (DBeQ) | B-23 | D 10.85 | | 83.80 | 1.59 | • | 1.55 | -6.40 | A B-1 analog: unknown mechanism (Bessoff, et al. 2014. AAC.); previously reported inhibitor of mammalian p87-ATPase and the unfolded protein response (Chou, et al. 2011. PMAS.) |
| 2,4-diaminoquinazoline B-5 | B-6 | D 7.22 | | 82.99 | -9.25 | 5 | 1.49 | 7.84 | B-1 analog: unknown mechanism. (Bessoff, et al. 2014. AAC.) |
| Allopurinol-based C-1 (MMV403679) | C-1 | G 0.65 | | -10.80 | 91.44 | 1 · · | 0.80 | 30.35 | C parwar growth inhibitor; unknown mechanism (Bessoff, et al. 2014. AAC.) |
| Allopurinol-based C-2 | C-2 | G 0.65 | | 3.65 | 98.27 | | 0.34 | 54.99 | C1 analog: unknown mechanism (Bessoff, et al. 2014, AAC.) |
| Allopurinol-based C-4 | C-4 | G 5.17 | | 9.11 | 99.18 | 8 | 0.48 | 64.12 | C C1 analog: unknown mechanism (Besself, et al. 2014. AAC.) |
| Allopurinol-based C-5 | C-5 | G 4.99 | | 13.07 | 98.17 | | 0.31 | 52.89 | C1 analog: unknown mechanism (Bessoff, et al. 2014, AAC.) |
| AN6426 (Leu-RS inhibitor) | | H 19.51 | | -16.44 | 86.81 | | 0.93 | 62.47 | LoughtRNA synthetase inhibitor previously reported to inhibit C ponum growth (Palancia, et al. 2016. AAC); presumed Cryptosporidum protein synthesis inhibitor |
| Atorvastatin | | P 2.18 | | -38.43 | -4.60 | | 1.88 | 36.34 | Ammalian HMG-CoA reductase inhibitor: inhibits C parvum rewith by areventing acquisition of host cell isoprenoid precursors (Bossoff, et al. 2013, AAC) |
| BKL1294 (CDPK1 inhibitor) | | 1 22.40 | | -6.64 | -5.73 | | 1.49 | 45.54 | Git come dependent protein binase (CDPC) 1 inhibitor with previously demonstrated anticryotosoporidal activity in SCID beine mice and the acute IPN + knockout mouse infection model (Castellanos-Gonzalez, et al. 2017, PLoS NTD, 1 additional anticryotosoporidal activity in SCID beine mice and the acute IPN + knockout mouse infection model (Castellanos-Gonzalez, et al. 2017, PLoS NTD, 1 additional anticryotosoporidal activity in SCID beine mice and the acute IPN + knockout mouse infection model (Castellanos-Gonzalez, et al. 2017, PLoS NTD, 1 additional anticryotosoporidal activity in SCID beine mice and the acute IPN + knockout mouse infection model (Castellanos-Gonzalez, et al. 2017, PLoS NTD, 1 additional anticryotosoporidal activity in SCID beine mice and the acute IPN + knockout mouse infection model (Castellanos-Gonzalez, et al. 2017, PLoS NTD, 1 additional anticryotosoporidal activity in SCID beine mice and the acute IPN + knockout mouse infection model (Castellanos-Gonzalez, et al. 2017, PLoS NTD, 1 additional anticryotosoporidal activity in SCID beine mice and the acute IPN + knockout mouse infection model (Castellanos-Gonzalez, et al. 2017, PLoS NTD, 1 additional anticryotosoporidal activity in SCID beine mice and the acute IPN + knockout mouse infection model (Castellanos-Gonzalez, et al. 2017, PLoS NTD, 1 additional anticryotosoporidal activity in SCID beine mice and the acute IPN + knockout mouse infection model (Castellanos-Gonzalez, et al. 2017, PLoS NTD, 1 additional anticryotosoporidal activity in SCID beine mice and the acute IPN + knockout mouse infection model (Castellanos-Gonzalez, et al. 2017, PLoS NTD, 1 additional anticryotosoporidal activity in SCID beine mice and the acute IPN + knockout mouse infection model (Castellanos-Gonzalez, et al. 2017, PLoS NTD, 1 additional anticryotosoporidal activity in SCID beine mice and the acute IPN + knockout mouse infection model (Castellanos-Gonzalez, et al. 2017, PLoS NTD, 1 additional anticryotosoporidal activity in SCID beine mice and the acute IPN + |
| BKI-1369 (CDPK1 inhibitor) | | L 17.65 | | -7.94 | 16.97 | | 1.41 | 41.93 | 8/1/12/4 analog with previously demonstrated anticycotoscoridal efficacy in enotobiotic given model (Lee, et al., 2018, AAC): additional anticycotoscoridal ehenotycic (#ficts not documented: #K)-12/94 inhibits Toxoplasma and Nessoora host cell (masion and errors (Winer, et al., 2015, AAC): Qio et al., 2014, PloS Dne. |
| BKL1553 (CDPK1 inhibitor) | | 3.49 | | .3.92 | 9.91 | | 1 94 | 31.8 | Bit 1294 analow with in vitro anticruotosopolial activity: additional anticruotosopolial benetivoic effects not documented: Bit-1294 inhibitsTosopolsmo and Neosopor host cell invasion and series (Winzer, et al. 2015, AAC. Dio, et al. 2014, PiloS One. 1 |
| BBD7929 (Phe-BS inhibitor) | | H 0.15 | | 0.40 | 93.39 | | 0.72 | 63.1 | Phone JRNA contribution in provide reported to inhibit Personalism foldonous ensure Licence and 2015. Nature 1- processed Controposition entration contracts inhibitory |
| Cindensorie di usud RS (ebibiter) | | H 0.40 | | | 02.10 | | 0.69 | 04.14 | (a) I (BM) antibative and antibio antibiotic lighthrough statistical lighthrough statistical (International Contractor) (International Contractor) (International Contractor) (International Contractor) |
| Cintarimino | | M 10.60 | | 66.45 | 00.00 | | 0.77 | 90.10 | preprior sponses and provem plantas manates with influence statistics (sequence) and one of plantas manates and plantas manates an |
| Department | | T 1.00 | · • | .9.62 | 10.00 | 1 | 1.70 | 27.03 | Manazola selentetar anna anti-indizia (abbien (anna anti-indizia) (abbien (anna anti-indizia) (abbien (anna anti-indizia) (abbien (abb |
| Decentre | | 1 1.00 | | 0.00 | 00.40 | | 0.74 | 7.01 | |
| Ploxing Males (MRR/2005044) | | J 0.14 | | -28.03 | 20,42 | | 4.07 | -7.5. | r yr man awsgy, C parwing growth ministerio (awsd), yr ac 2023. Aws (|
| Gentari viciel (NWV065041) | | B 1.05 | | -0.02 | 47.40 | , | 1.37 | 34.34 | A manuper reported mechanism of accord, c. ported my govern interaction (eds. 2014, eds.) |
| Habroghone (Proyt-RS Infibitor) | | H 0.34 | | 6.92 | 00.20 | | 0.69 | 00.23 | A ross-how symmetate minimizer with minimizer and an analyzing program and analyzing |
| Itraconazole | | 0 7.24 | | -29.72 | -4.85 | | 1.11 | 63.90 | |
| MMV001246 (ATG-8 inhibitor) | | 5.39 | | -7.41 | /2.11 | | 0.43 | 45.68 | A Rg5-Rg5 protein-protein interaction intributor and Plasmaduum growth initiator (Hain, et al. 2014. J Med Chem. J) (oxopaissing repictation initiator) (Varbeig, et al. 2014. ARC.) |
| MMV665909 (ATG-8 inhibitor) | | I 6.84 | | -12.01 | 90.80 |) | 0.41 | 53.05 | MNV001246 analog. Atg8-Atg3 protein-protein interaction inhibitor and Plosmodium growth inhibitor (Hain, et al. 2014. JMed Chem); Toxoplosmo replication inhibitor (Varberg, et al. 2018. AAC). C. porvum growth inhibitor; unknown mechanism (Bessoff, et al. 2014. AAC.) |
| Niotinib | | U 16.54 | • | -21.88 | 22.05 | 5 | 1.05 | 70.96 | Mammalian tyrosine kinase inhibitor; including BCX-ABL; c-Kit receptor kinase, and platelet-derived growth factor receptor-bata; phenotypic screening hit; unknown anticryptosportidal mechanism. |
| Nitazoxanide | | A 3.52 | | 13.83 | -9.16 | | 1.40 | 81.71 | In Trichomonos vaginalis, Entomorebo histolytica, Giardia intestinalis, Clostridium difficile, Clostridium diffici |
| Oryzalin | | S 1.49 | | 1.23 | 12.01 | | 2.39 | -48.24 | Binds Toxoplasma a Tubulin to disrupt microtubules (Morrissette, et al. 2004. Mol Bio Cell.); C. porvum growth inhibitor (Benbow, et al. 1998. AAC.); unknown anticryptosponidial mechanism. |
| P257 (IMPDH inhibitor) | | V 34.30 | | 9.88 | 97.76 | 3 | 0.84 | 70.52 | Copatosparidium inosine monophosphate delhydrogenase inhibitor; efficacious in the acute IL-12 knockout mouse model of cryptosparidiosis (Gorla, et al. 2014. AAC.) |
| Paromomycin | | R 2386 | .00 | -28.42 | 18.81 | | 2.15 | 43.80 | C parvum growth inhibitor; neomycin resistance assette shown to confer resistance (Vinayak, et al. 2015. Nature); active in NSG mouse model (Jumani, et al. 2018. A4C.) |
| Piperazine D-1 (MMV665917) | D-1 | K 5.10 | | -25.16 | 23.98 | 8 | 1.86 | 83.01 | C parvum growth inhibitor; unknown mechanism. Active in NSG mouse model (Jumani, et al. 2018. AAC.) |
| Piperazine D-28 | D-28 | K 1.50 | | -13.23 | 3.38 | 8 | 1.28 | 81.40 | D-1 analog; in vitro growth inhibitor; unknown mechanism (Jumani, et al. 2018. AAC.) |
| Piperazine D-44 | D-44 | K 11.60 | | -11.48 | 12.07 | | 2.21 | 74.35 | D-1 analog; in vitro growth inhibitor; unknown mechanism (Jumani, et al. 2018. AAC.) |
| Pyrvinium pamoete | | C 3.21 | | 25.69 | 88.30 | 5 | 0.61 | 68.07 | Multiple reported mechanisms of action; previously demonstrated anticryptosporidial activity in neonatal mouse model (Downey, et al. 2008. AAC.) |
| Quinclinol A-2 (MMV665814) | A-2 | N 1.34 | | -15.19 | 100.00 | | 0.69 | 36.33 | C panum growth inhibitor; unknown mechanism (Bessoff, et al. 2014. AAC.) |
| Quinclinol A-5 (MMV666080) | A-5 | N 4.35 | | -13.46 | 99.95 | | 0.32 | 65.35 | A 2 analog. C, panum growth inhibitor: unknown mechanism (Bessoff, et al. 2014, AAC.) |
| Quinclinol A-6 (MMV000760) | A-6 | N 1.33 | | -20.21 | 89.49 | | 0.79 | 17.23 | A-2 analyse. C parvum growth inhibitor: unknown mechanism (Bessoff, et al. 2014, AAC) |
| Tegaserod | | F 10.32 | | 13.93 | -6.72 | 2 | 1.01 | 12.05 | Mammalian seretorini Trope 4 (5-H), receptor partial azonist: C. parvum growth inhibitor; uninown anticryotosporidial mechanism Bessoff et al. 2013. AAC.) |
| Torkinih | | E 0.26 | | -21.41 | .10.10 | | 1.61 | 44.44 | |
| 1M/2002 (Mot PR inhibitor) | | L 0.36 | | .0.02 | -10.10 | | 1.00 | 7.70 | Intermination of the second processing in generating in generating in generating processing procesing processing processing processing processing proc |
| Wickertate (MEA/2002) | | 0 11.2/ | | 99.59 | 26.20 | | 1.04 | 46.76 | Analysis in the second period of the second se |
| (marc/2367) | | × 11.34 | | 00.00 | 30.33 | | 1.04 | | |

The construction of the co

Supplementary Table 3: Summary of in vivo efficacy in NOD SCID Gamma (NSG) mouse model of cryptosporidiosis.

| Date Date Date Date Non-row Non-row <th><u>,</u></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th>% reduction in fecal</th> <th>p-value</th> | <u>,</u> | | | | | | | % reduction in fecal | p-value |
|---|--|--|-----------------------|----------|----------|--|-----------|------------------------------|---------------|
| Control D Salar (rulg (col grand) (rulg (col grand) (rulg (col grand) (rulg (col grand)) (rul g (col gran)) | | | Dose | Interval | Duration | | NSG mouse | oocyst shedding vs. | (student's t- |
| 2: 4 destinguisation 4:1 (MAND 97) Chem (MAND 97) Chem (MAND 97) Chem (MAND 97) NA 2: 4 destinguisation 4:1 (MAND 97) Chem (MAND 97) Chem (MAND 97) NA 2: 4 destinguisation 4:1 (MAND 97) Chem (MAND 97) Chem (MAND 97) NA 2: 4 destinguisation 4:1 (MAND 97) Chem (MAND 97) NA NA 2: 4 destinguisation 4:1 (MAND 97) Chem (MAND 97) NA NA 2: 4 destinguisation 4:1 (MAND 97) Chem (MAND 97) NA NA 2: 4 destinguisation 4:1 (MAND 97) Chem (MAND 97) NA NA 2: 4 destinguisation 4:1 (MAND 97) Chem (MAND 97) NA NA 2: 4 destinguisation 4:1 (MAND 97) Chem (MAND 97) Chem (MAND 97) NA NA 2: 4 destinguisation 4:1 (MAND 97) Chem (MAND 97) Chem (MAND 97) NA NA 2: 4 destinguisation 4:1 (MAND 97) Chem (MAND 97) Chem (MAND 97) NA NA 2: 4 destinguisation 4:1 (MAND 97) Chem (MAND 97) Chem (MAND 97) NA NA 2: 4 destinguisation 4:1 (MAND 97) Chem (MAND 97) Chem (MAND 97) | Compound ID | Smiles | (mg/kg (oral gavage)) | (h) | (days) | Vehicle | efficacy | vehicle control ^a | test) |
| 2.4.dem 0.4.dem | 2,4-diaminoquinazoline B-1 (MMV006169) | C(Nc1nc(Nc2ccccc2)nc3ccccc13)c4ccccc4 | 50.0 | 12 | 4 | 1% HPMC / 5% DMSO | No | NA | / |
| 24.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4. | 2,4-diaminoquinazoline B-13 | COc1ccc(cc1Cl)Nc1nc(NCc2ccccc2Cl)c2c(n1)cccc2 | 50.0 | 12 | 4 | 1% HPMC / 5% DMSO | No | NA | |
| 24-distant (Distance) Clock (Distance) Clock (Distance) Distance | 2,4-diaminoquinazoline B-23 (DBeQ) | c1ccc(cc1)CNc1nc(NCc2ccccc2)c2c(n1)cccc2 | - | - | - | - | ND | NA | |
| Alignet of Sector (MM/V359) Intermediated SCI_MM/V3590 Intermediated SCI_MM/V3590 Intermediated SCI_MM/V3590 No No Alignet of Sector (SCI_MM/V3590) Intermediated SCI_MM/V3590 Intermediated SCI_MM/V3590 No No No No Alignet of Sector (SCI_MM/V3590) Intermediated SCI_MM/V3590 Intermediated SCI_MM/V3590 No No No No Alignet of Sector (SCI_MM/V3590) Intermediated SCI_MM/V3590 Intermediated SCI_MM/V3590 No No No No Alignet of Sector (SCI_MM/V3590) Intermediated SCI_MM/V3590 Intermediated SCI_MM/V3590 No No No No Alignet of Sector (SCI_MM/V3590) Intermediated SCI_MM/V3590 Intermediated SCI_MM/V3590 No No No No No Alignet of Sector (SCI_MM/V3590) Intermediated SCI_MM/V3590 Intermediated SCI_MM/V3590 No No No No Sector (SCI_MM/V3590) Intermediated SCI_MM/V3590 Intermediated SCI_MM/V35900 No No No Sector (SCI_MM/V3590) Intermediated SCI_MM/V35900 Intermediated SCI_MM/V359000 No | 2,4-diaminoquinazoline B-5 | C1CCC(C1)Nc1nc(NCc2cccc2)c2c(n1)cccc2 | 50.0 | 12 | 4 | 1% HPMC / 5% DMSO | No | NA | |
| Alloy Lands and C - A strong in Calcon (CS) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C | Allopurinol-based C-1 (MMV403679) | c1(c(cnn1c2cccc(C)c2)C(=O)N3)N=C3n4nc(C)cc4NC(=O)c5cc(cccc6)c6o5 | - | - | - | - | ND | NA | |
| Alley units based C-4 State of the State of Control Co | Allopurinol-based C-2 | c31c(cnn1-c2cc(ccc2)C)C(=O)NC(=N3)n4c(cc(n4)C)NC(=O)c5c(cc(cc5)OC)OC | 100.0 | 24 | 7 | 1% HPMC / 5% DMSO | No | NA | |
| Allegate Allegate Allegate Allegate Control Part Number of the Control | Allopurinol-based C-4 | c31c(cnn1-c2cc(ccc2)C)C(=O)NC(=N3)n4c(cc(n4)C)NC(=O)C5CC5 | 100.0 | 24 | 7 | 1% HPMC / 5% DMSO | No | NA | |
| NAME22 Control Control <th< td=""><td>Allopurinol-based C-5</td><td>c31c(cnn1-c2cc(ccc2)C)C(=O)NC(=N3)n4c(cc(n4)C)NC(=O)C5CCCC5</td><td>100.0</td><td>24</td><td>7</td><td>1% HPMC / 5% DMSO</td><td>No</td><td>NA</td><td></td></th<> | Allopurinol-based C-5 | c31c(cnn1-c2cc(ccc2)C)C(=O)NC(=N3)n4c(cc(n4)C)NC(=O)C5CCCC5 | 100.0 | 24 | 7 | 1% HPMC / 5% DMSO | No | NA | |
| CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC | AN6426 (Leu-RS inhibitor) | OB1OC(CN)C2=C(CI)C=CC(OCC)=C21 | 60.0 | 24 | 4 | 1% CMC/0.1% Tween | No | NA | |
| Above statish Mcd=CC=CC Mcd A Mode Statish Mcd Mcd Mcd BK12364 (CDFK1 inhibitity) CCCC(CC+1C)=CC=C2230+MICC4CCNC(EC24C56+NIC+NIC/HC35 B.0. 24 4 90% Silline:/%T Weenf83,24850H /90% Silline Mcd Mcd BK12364 (CDFK1 inhibitity) CCCC(CC+1C)=CC=C2230+MICC4CCNC(EC24C56+NIC+NIC/HC35 B.0. 24 4 90% Silline:/%T Weenf83,24850H /90% Silline Mcd B24 000 Mcd B24 B24 B25 Mcd B24 B25 Mcd D26 D | | CC(C)C1=C(C(=C(N1CCC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O) | 50.0 | 12 | 7 | | No | NΔ | |
| Bit 124 (CDPK 1 inhibitor) CDC0(CC+1)=CDC1C+02)=CDC253+NIXC4CAC(NC)CC4(CS+NC+CC4CN(NC>55 0.00 24 4 95K (MAG 95% (DTW cereB3/98% CDH Q0)SSIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII | Atorvastatin | NC4=CC=CC=C4 | 50.0 | 12 | 1 | 1% HPMC / 5% DMSO | NO | | |
| Bit 1380 (DEPKI inhibito) CDC/CPC IN MCC In C/D | BKI-1294 (CDPK1 inhibitor) | CCOC(C=C1)=CC(C1=C2)=CC=C2C3=NN(CC4CCN(C)CC4)C5=NC=NC(N)=C53 | 100.0 | 24 | 4 | 5% DMSO 95%[7%Tween80/3%EtOH/90%Saline] | No | NA | |
| BK1-1033 COPEC Initiation First Society CopeCopeCopeCopeCopeCopeCopeCopeCopeCope | BKI-1369 (CDPK1 inhibitor) | CCOC(C=C1)=NC(C1=C2)=CC=C2C3=NN(CC4CCN(C)CC4)C5=NC=NC(N)=C53 | 60.0 | 24 | 4 | 90% Saline:7% Tween80:3%Etoh | Yes | 90.8% | 0.03 |
| No. No. Oct 1, Markan Strate No. | BKI-1553 (CDPK1 inhibitor) | NC1=C2C(N(CC(O)(C)C)N=C2C3=CC=C(C=C(OC4CC4)C=C5)C5=C3)=NC=N1 | 10.0 | 24 | 4 | 90% Saline:7% Tween80:3% Ftoh | Yes | 81.2% | 0.04 |
| BRD7802 (Pha-RS inhibitor) CCIC/CCIC/CIC/CCCC/CIC/CCC/CIC/CIC/CIC/ | | CN(C)CC1C(C2N1CCCCN(C2)C(=O)NC3=CC=C(C=C3)OC)C4=CC=C(C=C4)C#CC5=CC | ; | 27 | 7 | | 103 | 01.270 | 0.04 |
| Caldspace CaldCode Code (Code (C | BBD7929 (Phe-RS inhibitor) | =CC=C5 | 10.0 | 24 | 4 | 0.5% HPMC 0.5% Tween 80/ 5% DMSO | Yes | 99.9% | 0.02 |
| Charamics COC(0)N=C1C-C2C(C+C)C3C-CC-CC)(N+CC-C)C(C-C)(C)C-CC-CC)(C+C | Cladosporin (I vsvI-RS inhibitor) | CC1CCCC(01)CC2CC3=CC(=C3C(=0)02)0)0 | - | - | - | - | ND | NA | |
| Characterization Control Contr | | | 100.0 | 04 | 4 | | Ne | | |
| Chiral Coll (C) CDC (C) (C) (C) (C) (C) (C) (C) (C) (C) (C | Clofazimine | CC(C)N=CTC=C2C(=NC3=CC=CC3N2C4=CC=C(C=C4)CI)C=CTNC5=CC=C(C=C5)CI | 100.0 | 24 | 4 | Corn Oil or .5% HPMC, 0.5% Tween 80/ 5% DMSO | INO | NA | |
| Docessarial CC/C/C/C/C/C/C/C/C/C/C/C/C/C/C/C/C/C/C | | CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=C5)NC(=O)O | | | | | | NΙΛ | |
| Flow dink C1C(CQC1M2cOC(P)CQC) C1C(CQC1M2cOC(P)CQC) C20 C S S S S Geninal Violet (MV665941) C1C(CQCM2CVGC2MCQCQCQCQCQCQCQCQCQCQCQCQCQCQCQCQCQCQC | Docetaxel | C(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O | - | - | - | - | ND | INA | |
| Genita Nucle (MW4656814) Haldbaginer (Prop. PS: hill) CNC/c (Face/CC (C)C/C)(C)(C)(C)(C)(C)(C)(C)(C)(C)(C)(C)(C)(C | Floxuridine | C1C(C(OC1N2C=C(C(=O)NC2=O)F)CO)O | 200.0 | 24 | 7 | 1% HPMC / 5% DMSO | No | NA | |
| Haldsdippione (ProgyLRS: Inhibitor) C1C/C (DNC1)C/C (C/C (C/C (C/C (C/C (C/C (C/C (C/C | Gentian Violet (MMV665941) | CN(C)c1ccc(cc1)C(O)(c2ccc(cc2)N(C)C)c3ccc(cc3)N(C)C | 50.0 | 12 | 4 | 1% HPMC / 5% DMSO | No | NA | |
| CCCC(D)NIC=N1/C2=CC=C[C=C2]N3CCN(C2]3/C4=CC=C[C=C4]OCCSCOC(C6] 50.0 12 7 1% HPMC / 5% DMSO No Na MMV001246 (ATG-B inhibitor) CS fecocc1(C=OVACIC)C=CC=CTC)CI(C) 50.0 12 4 1% HPMC / 5% DMSO No Na MMV001246 (ATG-B inhibitor) CS fecocc1(C=OVACIC)C=CC=CC=CIC)(C)(C)(C) 50.0 12 4 1% HPMC / 5% DMSO No Na Nilotrib Canne(d) face(NC=Q)Scacca3 50.0 12 4 1% HPMC / 5% DMSO No Na Nilotrib Canne(d) face(NC=Q)Scacca3) 200.0 24 7 1% HPMC / 5% DMSO No Na Nilotrib CC(=C)CCCCCC+CIN(H=[O)(2)S(=C)C=CCC)(C)(P(P)FE)C2)=C)=C1)C 8.0 8 4 90% Saline;7% Tween80;3%Etch No Na P257 (MPDH inhibitor) INH3+CCOCCCC+CCC(C)C(C)(C)(C)(C)(C)CCCCC)CCCCCC) 30.0 12 4 1% HPMC / 5% DMSO Yes 92.9% 0.01 Paromonyoin (N)(O)(O) S(=O)(C) (N)(O)(O)(O)(O)(C)(C)(C)CCCCC)(C)(C)(C)(C)(C)CCCC) 2 4 1% HPMC / 5% DMSO Yes 92.9% 0.01 | Halofuginone (Propyl-RS inhibitor) | C1CC(C(NC1)CC(=O)CN2C=NC3=CC(=C(C=C3C2=O)CI)Br)O | - | - | - | - | ND | NA | |
| Ittaconacio (CM6CHXCHaig)CF2C(C=C)C(C)(C) Control of the CMC and the CMX and the | | CCC(C)N1C(=0)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5) |) = 0 0 | 40 | - | | | | |
| MMV01248 (ATS-8 Initibitity) Sci Ecoccct C(=)/MC2n(ccs)/25000073 50.0 12 4 1% HPMO (5% DMSO No Na MMV065899 (ATG-8 Initibitity) Bot Concort (C=)/MC2n(ccs)/25000073 50.0 12 4 1% HPMO (5% DMSO No Na Nitato Cation (1) cloc(NC(=0)/25000(C)(N30000(3)/35000073)/2)ccl(C)(F)(F)F 20.0 24 7 % HPMO (5% DMSO No Na Nitato Cation (1) cloc(NC(=0)/25000(C)(N30000(3)/35000073)/2)ccl(C)(F)(F)F)-C2)=0)=(1) 30.0 24 7 % HPMO (5% DMSO No Na Organin Cation (C)(C)(C)(C)(C)(C)(C)(C)(C)(C)(C)(C)(C)(| Itraconazole | (CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl | 50.0 | 12 | 1 | 1% HPMC / 5% DMSO | NO | NA | |
| MMV665909 (ATG-8 inhibitor) Brd tocccc 10(ci 0)(k2.m(ci 2)/ds2x0cm3)/c2.0(ci 1)(F)(F) 50.0 12 4 19M0/1500 No NA Nilotinib Chan(ci 1)tack(NC(20)/c2.2x0cC)/c3(Nc3nc3/c2)c(ci 1)(F)(F) 20.0 24 7 19HPMC / 5% DMSO No NA Nilotizabande CC(-0)OC1=CC-CC-C1(C)(-0)NC2+NC=C(S2)(H)(-0)(-) 200.0 24 7 19HPMC / 5% DMSO No NA Dysalin CC(-0)OC1=CC-CC-C1(C)(D)NC2+NC=CC(S2)(H)(P)(F)F)F=C2)=OP(-1)(C 83.0 8 90% Saline;7% Twee80.3%Etoh No NA Paromonycin (D(C)C(C)(C1)(D)C2/C)(C(C)(2)(D)O)(D)NC3(C)(C)(C)(2)(D)O)(D)C3(C)(C)(C)(C)(C)(C)(C)(C)(C)(C)(C)(C)(C)(| MMV001246 (ATG-8 inhibitor) | CSc1ccccc1C(=O)Nc2nc(cs2)c3ccccn3 | 50.0 | 12 | 4 | 1% HPMC / 5% DMSO | No | NA | |
| Nitation Cation(c1)c1cc(NC(=0)c2cocC()c(NC3ncc(n3)c3cocn3)c2)cc(1)C(F)(F) 42.0 8 4 90% Saline;7% Tween80;3%Etch No Na Nitazxanide CC(=0)C1=CC=CC=C1(=0)NC2=NC=(S2 N+1(=0)]-0] 20.0.0 24 7 1% HPMC / 5% DMSO No Na 0/zalin CC(CN(CC)(=1CC=CC)C(C)(C)(NC(NC2=CC=C(C)(C)(C)(F)(F)F)=C2)=0)=C1)C 83.0 8 4 90% Saline;7% Tween80;3%Etch No Na P257 (IMPDH inhibitar) (NH3+)CC0/N=C(C1=CC=CC)(C)(C)(NC(NC2=CC=C(C)(C)(C)(F)(F)F)=C2)=0)=C1)C 83.0 8 4 90% Saline;7% Tween80;3%Etch No Na Paromomycin C1C(C)(C)(C1C)C2C)CC(C)(C2)C3ccod-nner4n3)cc1 80.0 12 4 1% HPMC / 5% DMSO Yes 98.9% 0.01 Piperazine D-1 (MWYG65917) C1ctocc(NC)(=0)N/CCCN(C2)c3ccod-(NICC1)c1ccc2:n(NIC(=C)C)CC)(C) 60.0 12 4 1% HPMC / 5% DMSO Yes 99.9% 0.01 Piperazine D-4 O=C(NTCCN(C)C)C1ccc2:N(CC)C)C1cCCC)(C)CC(C)CCC)CC C - - - ND NA Outcoling A-2 (MWYG656814) O=C(NTCCN(C)C)CCCC)C=CC)CC(C)CCC)(C)CC)CCC)CC - < | MMV665909 (ATG-8 inhibitor) | Brc1ccccc1C(=O)Nc2nc(cs2)c3ccccn3 | 50.0 | 12 | 4 | 1% HPMC / 5% DMSO | No | NA | |
| Nitazoanide CC(=0)OC1=CC=CC=C1(q=())C(2=NC=C(S2)[N+](=0)[O_1] 200.0 24 7 % HPMC / 5% DMSO No Na Organin CCC(CC)C1=C(C=CC)(C+[N+](D)(D)S)=(O)(=O)(N)[N+]=(D)(O) Salon 8 90% Saline;7% Tween80;3%Etoh No Na P257 (IMPDH inhibitor) INH3H2COZNIC(C)(C2C)C2CC)(C)(C)(C)(C)(C2C)C2C)(C)(C)(C)(C)(C)(C)(C)(C)(C)(C)(C)(C)(C | Nilotinib | Cc1ncn(c1)c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)c3cccnc3)c2)cc(c1)C(F)(F)F | 42.0 | 8 | 4 | 90% Saline;7% Tween80;3%Etoh | No | NA | |
| Mazzanide Conversion Conversi | Nitazovanide | CC(=0)OC1=CC=CC=C1C(=0)NC2=NC=C(S2)IN+1(=0)IO-1 | 200.0 | 24 | 7 | | No | NA | |
| Organity Operating Conjection (Conjection) (Conjectin) (Conjection) (Conjectin) (Conjection) (Conjection) (C | | CCCN(CCC)C1=C(C=C1[N]+1(=C)[C-1]S(=C)(=C)N(E)[N+1(=C)[C-1]) | | | _ | | ND | ΝΔ | |
| P257 (MPDH inhibitor) [MH3PCCONAC(C) (CC/C)(C)(C)(C)(C)(C)(C)(C)(C)(C)(C)(C)(C)(C | | | - | - | - | - | | | |
| Paromonycin OINO/ONLOS(=0)(=0) 200.0 24 4 1% HPMC / 5% DMSO Yes 9.2% 0.03 Piperazine D-1 (MMV665917) Clctocc(NC(=0)N2CCN(CC2)c3ccc4nncn4n3)cc1 30.0 12 4 1% HPMC / 5% DMSO Yes 9.9% 0.01 Piperazine D-28 O=C(N1CCN(CC1)eloc2cn(11)enn2)Ne1cec2(cl(cl)CD)(1 60.0 12 4 1% HPMC / 5% DMSO Yes 9.9% 0.01 Piperazine D-28 O=C(N1CCN(CC1)eloc2cn(11)enn2)Ne1cec2(cl(cl)(CC)(1)CCCC)(=1cc2n(11)enn2)Ne1cec2(cl)(Cl)(CC)(=1cc2n(1)CC)(=1cc2n(1)CCC)(=1cc2n(1)CC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1ccC(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1ccC(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1ccC(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1cc2n(1)CCC)(=1ccC(1)CCC)(=1cc2n(1)CCC)(=1ccC(1)CCC)(=1cc2n(1)CCC)(=1ccC(1)CCC)(=1ccC(1)CCC)(=1ccC(1)CCC)(=1ccC(1)CCC)(=1ccC(1)CCC)(=1ccC(1)CCC)(=1ccC(1)CCC | P257 (IMPDH inhibitor) | [NH3+]000/N=0(01=00=00(0(0)(0)N0(N02=00=0(0))0(0(F)(F)F)=02)=01)\0 | 83.0 | 8 | 4 | 90% Saline;7% Tween80;3%Etoh | NO | NA | |
| Paromonycin O/N/O/O/N.OS(=O/(=O)O Locotic Locotic <thlocotic< th=""> Locotic Locoti</thlocotic<> | | C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)O)N)OC3C(C(C(O3)CO)OC4C(C(C(C(O4)CN)O |) 2000 0 | 24 | 4 | | Yes | 92 9% | 0.03 |
| Piperazine D-1 (MW0665917) Clc1ccc(NC(2=0)N2CCN(C2=2)d3cc4nna/h3)cc1 30.0 12 4 1% HPMC / 5% DMSO Yes 98.9% 0.01 Piperazine D-28 O=C(N1CCN(C1)c1acc2n(n1)cnn2)Nc1coc(c(1)Cl)CC1 60.0 12 4 1% HPMC / 5% DMSO Yes 99.9% 0.01 Piperazine D-44 O=C(C1ccc(c1)S(=0)(-C)N(C)C)N1CCN(CC1)c1cc2n(n1)cnn2 - - - - ND NA S=CC6BCC=CC(N+1)(C)=C2C=CC1)(C=C/G3=C(N(C4=CC=CC=C4)C(C)=G3)(C)C.OC(C9=C7)(C).C | Paromomycin | O)N)O)N.OS(=O)(=O)O | 2000.0 | 27 | - | 1% HPMC / 5% DMSO | 100 | 02.070 | 0.00 |
| Piperazine D-28 O=C(N1CCN(CC1)c1ccc2n(n1)cn2)Nc1ccc(c(c1)C)C1 60.0 12 4 1% HPMC / 5% DMSO Yes 99.9% 0.01 Piperazine D-44 O=C(N1CCN(CC1)c1ccc2n(n1)cn2)Nc1CCN(CC1)c1ccc2n(n1)cn2 - | Piperazine D-1 (MMV665917) | Clc1ccc(NC(=O)N2CCN(CC2)c3ccc4nncn4n3)cc1 | 30.0 | 12 | 4 | 1% HPMC / 5% DMSO | Yes | 98.9% | 0.01 |
| Piperazine D-44 O=C(ctoc(cc1)S(=0)(-0)(N(C)(L)(1c)cc2cn(1)(nn2) - | Piperazine D-28 | O=C(N1CCN(CC1)c1ccc2n(n1)cnn2)Nc1ccc(c(c1)Cl)Cl | 60.0 | 12 | 4 | 1% HPMC / 5% DMSO | Yes | 99.9% | 0.01 |
| CN(01=C02=C0=C([N+](C)=C02=C1)/C=C/C/G3=C(N(C4=C0=C0=C4)C(C)=C3)C)C.CN(C2 1 7 No Na Pyrvinium pamoate \$=C06=C0=C(N)(N=C)/C=C0C(N12=CC(C0))/C=C/C1=CC(N12=CC(C0))/C=C/(N12=CC)/CC(N12=CC)/(C)/C2=CC)/(C)/(C)/(C)/C2=CC)/(C)/(C)/(C)/(C)/(C)/(C)/(C)/(C)/(C)/ | Piperazine D-44 | O=C(c1ccc(cc1)S(=O)(=O)N(C)C)N1CCN(CC1)c1ccc2n(n1)cnn2 | - | - | - | - | ND | NA | |
| 5=CC6=CC=C([N+](C)=C6C=C5)/C=C/C7=C(N(C8=CC=CC=C8)C(C)=C7)C(C.OC(C9=CC 2.5) 12 7 No Na Pyrvinium pamoate %10=CC=CC=C%10C(CC4=CC(N1=C%12=CC=CC%12=CC(C(0)=0)=C%110)=C90)=0 1% HPMC / 5% DMSO No Na Quinolinol A-2 (MMV665814) Oc1c(ccc2cccnc12)C(Nc3cccc3)c4ccccc4 50.0 12 4 1% HPMC / 5% DMSO No Na Quinolinol A-5 (MMV666808) Oc1c(ccc2cccnc12)C(NC(=O)C3ccccc3)c4ccccc4 50.0 12 4 1% HPMC / 5% DMSO No Na Quinolinol A-6 (MMV000760) Oc1c(CN2CCN(CC2)c3ccccc3)Foc(Br)c4ccnc14 - | | CN(C1=CC2=CC=C([N+](C)=C2C=C1)/C=C/C3=C(N(C4=CC=CC=C4)C(C)=C3)C)C.CN(C | | | | | | | |
| Pyroinium pamoate %10=CC=CC%10C(C0%11=C%12C=CC=C%12=CC(C0)=0)=C%110)=C90)=0 1% HPMC / 5% DMS0 No NA Quinolinol A-2 (MMV665814) Oc1c(ccc2cccnc12)C(Nc3cccc3)c4cccc4(0c5cccc5)c4 50.0 12 4 1% HPMC / 5% DMS0 No NA Quinolinol A-5 (MMV666080) Oc1c(ccc2cccnc12)C(Nc3cccc3)c4cccc4 50.0 12 4 1% HPMC / 5% DMS0 No NA Quinolinol A-6 (MMV000760) Oc1c(cc2cccnc12)C(NC2)c3ccccc3F)cc(Br)c4cccnc14 - < | | 5=CC6=CC=C([N+](C)=C6C=C5)/C=C/C7=C(N(C8=CC=CC=C8)C(C)=C7)C)C.OC(C9=CC | 2.5 | 12 | 7 | | No | NA | |
| Quinolinol A-2 (MMV665814) Oc1c(ccc2cccn12)C(Nc3ccccn3)c4cccc(Oc5cccc5)c4 50.0 12 4 1% HPMC / 5% DMSO No NA Quinolinol A-5 (MMV66080) Oc1c(ccc2cccn12)C(Nc(=O)c3ccccc3)c4ccccc4 50.0 12 4 1% HPMC / 5% DMSO No NA Quinolinol A-5 (MMV00760) Oc1c(CC2cccn12)C(NC(=O)c3ccccc3)c4ccccc4 50.0 12 4 1% HPMC / 5% DMSO No NA Quinolinol A-6 (MMV00760) Oc1c(CN2CCN(CC2)c3cccc3)Fc(Br)c4cccnc14 - - - - - - - ND NA Tegaserod CCCCN=C(N)NNC=C1C=NC2=C1C=C(C=C2)OC.(=C2)OC.(=C2(C=O)O)C(=O) 200.0 24 7 1% HPMC / 5% DMSO NO NA UW2093 (Met-RS inhibitor) ClC1=CC([CH3]=O)=CC=C1CC(N2CC)=CN(CC3=NC(C=C2)OLC(C)=N4)=C4N3)C2=O 20.0 2 4 90% Saline;7% Tween80;3%Etoh NO NA UW2093 (Met-RS inhibitor) ClC1=CC([CH3]=O)=CC=C1CC(N2C)=CN(CC)=N4)=C4N3)C2=O 30.0 12 4 1% HMC 0.5% Tween80;3%Etoh No NA Wiskostatin (MMV672987) OR BrC(=C3=CC1=C3N(CC(O)CN(C)C)C2=C1C=C(Br)C=C2 30.0 <th< td=""><td>Pyrvinium pamoate</td><td>%10=CC=CC=C%10C(CC%11=C%12C=CC=CC%12=CC(C(O)=O)=C%11O)=C9O)=O</td><td></td><td></td><td></td><td>1% HPMC / 5% DMSO</td><td></td><td></td><td></td></th<> | Pyrvinium pamoate | %10=CC=CC=C%10C(CC%11=C%12C=CC=CC%12=CC(C(O)=O)=C%11O)=C9O)=O | | | | 1% HPMC / 5% DMSO | | | |
| Quinolinol A-5 (MMV666080) Oc1c(ccc2cccn12)C(NC(=O)c3ccccc3)c4ccccc4 50.0 12 4 1% HPMC / 5% DMSO No Na Quinolinol A-6 (MMV000760) Oc1c(CN2CCN(CC2)c3ccccc3F)cc(Br)c4ccnc14 - - - - - ND NA Tegaserod CCCCN=C(N)NNC=C1C=NC2=C1C=C(C=C2)OC.C(=CC(=O)O)C(=O)O 200.0 24 7 1% HPMC / 5% DMSO No NA Torkinib CC(C)N1C2=C(C(=C3C=C4C=C(C=CC4=N3)O)N1)C(=NC=N2)N 42.0 8 4 90% Saline;7% Tween80;3%Etoh No NA UW2093 (Met-RS inhibitor) ClC1=CC([CH3]=O)=CC=C1CC(N2CC)=CN(CC3=NC(C=CC(E)=N4)=C4N3)C2=O 50.0 12 4 1% HMC 0.5% Tween80 Yes 94.6% 0.03 OC R BrC(C=C3)=CC1=C3N(CC(O)CN(C)C)C2=C1C=C(Br)C=C2 30.0 12 4 1% HPMC / 5% DMSO No NA Wiskostatin (MMV672987) OR CN(C)CC(CN1C2=C(C=C2)Br)C3=C1C=CC(=C3)Br)O 30.0 12 4 1% HPMC / 5% DMSO No NA | Quinolinol A-2 (MMV665814) | Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4cccc(Oc5ccccc5)c4 | 50.0 | 12 | 4 | 1% HPMC / 5% DMSO | No | NA | |
| Quinolial A-6 (MMV000760) Oc1c(CN2CCN(CC2)c3cccc3F)cc(Br)c4cccnc14 - </td <td>Quinolinol A-5 (MMV666080)</td> <td>Oc1c(ccc2cccnc12)C(NC(=O)c3ccccc3)c4ccccc4</td> <td>50.0</td> <td>12</td> <td>4</td> <td>1% HPMC / 5% DMSO</td> <td>No</td> <td>NA</td> <td></td> | Quinolinol A-5 (MMV666080) | Oc1c(ccc2cccnc12)C(NC(=O)c3ccccc3)c4ccccc4 | 50.0 | 12 | 4 | 1% HPMC / 5% DMSO | No | NA | |
| Tegaserod CCCCCN=C(N)NNC=C1C=NC2=C1C=C(C=C2)OC.C(=CC(=O)O)C(=O)O 20.0 24 7 1% HPMC / 5% DMSO No NA Torkinib CC(C)N1C2=C(C(=C3C=C4C=C(C=C2)AC(C=CC4=N3)O)N1)C(=NC=N2)N 42.0 8 4 90% Saline;7% Tween80;3%Etoh No NA UW2093 (Met-RS inhibitor) CIC1=CC([CH3]=O)=CC=C1CC(N2CC)=CN(CC3=NC(C=CC(D)=N4)=C4N3)C2=O 50.0 12 4 1%HMC 0.5% Tween80 Yes 94.6% 0.03 OC(CN(C)C)CN1C2=CC=C(Br)C=C2C3=C1C=CC(Br)=C3 OR BrC(C=C3)=CC1=C3N(CC(O)CN(C)C)C2=C1C=C(Br)C=C2 30.0 12 4 1% HPMC / 5% DMSO No NA Wiskostatin (MMV672987) OR CN(C)CC(CN1C2=C(C=C2)Br)C3=C1C=CC(=C3)Br)O 30.0 12 4 1% HPMC / 5% DMSO No NA | Quinolinol A-6 (MMV000760) | Oc1c(CN2CCN(CC2)c3ccccc3F)cc(Br)c4cccnc14 | - | - | - | - | ND | NA | |
| Torkinib CC(C)N1C2=C(C(=C3C=C4C=C(C=CC4=N3)O)N1)C(=NC=N2)N 42.0 8 4 90% Saline;7% Tween80;3% Etoh No NA UW2093 (Met-RS inhibitor) CIC1=CC([CH3]=O)=CC=C1CC(N2CC)=CN(CC3=NC(C=CC(CI)=N4)=C4N3)C2=O 50.0 12 4 1% HMC 0.5% Tween80;3% Etoh Yes 94.6% 0.03 OC(CN(C)C)CN1C2=CC=C(Br)C=C2C3=C1C=CC(Br)=C3 OR BrC(C=C3)=CC1=C3N(CC(O)CN(C)C)C2=C1C=C(Br)C=C2 30.0 12 4 1% HPMC / 5% DMSO No NA Wiskostatin (MMV672987) OR CN(C)CC(CN1C2=C(C=C2)Br)C3=C1C=CC(=C3)Br)O 30.0 12 4 1% HPMC / 5% DMSO No Na | Tegaserod | CCCCCN=C(N)NNC=C1C=NC2=C1C=C(C=C2)OC.C(=CC(=O)O)C(=O)O | 200.0 | 24 | 7 | 1% HPMC / 5% DMSO | No | NA | |
| UW2093 (Met-RS inhibitor) CIC1=CC([CH3]=0)=CC=C1CC(N2CC)=CN(CC3=NC(C=CC(D)=N4)=C4N3)C2=O 50.0 12 4 1%HMC 0.5% Tween80 Yes 94.6% 0.03 OC(CN(C)C)CN1C2=CC=C(Br)C=C2C3=C1C=CC(Br)=C3 OC(CN(C)C)CN1C2=CC=C(Br)C=C2C3=C1C=CC(Br)C=C2 30.0 12 4 1%HMC 0.5% Tween80 No No <td>Torkinib</td> <td>CC(C)N1C2=C(C(=C3C=C4C=C(C=CC4=N3)O)N1)C(=NC=N2)N</td> <td>42.0</td> <td>8</td> <td>4</td> <td>90% Saline;7% Tween80;3%Etoh</td> <td>No</td> <td>NA</td> <td></td> | Torkinib | CC(C)N1C2=C(C(=C3C=C4C=C(C=CC4=N3)O)N1)C(=NC=N2)N | 42.0 | 8 | 4 | 90% Saline;7% Tween80;3%Etoh | No | NA | |
| OC(CN(C)C)CN1C2=CC=C(Br)C=C2C3=C1C=CC(Br)=C3 OR BrC(C=C3)=CC1=C3N(CC(0)CN(C)C)C2=C1C=C(Br)C=C2 30.0 12 4 No Na Wiskostatin (MMV672987) OR CN(C)CC(CN1C2=C(C=C2)Br)C3=C1C=CC(=C3)Br)O 12 4 1% HPMC / 5% DMSO Na | UW2093 (Met-RS inhibitor) | CIC1=CC([CH3]=O)=CC=C1CC(N2CC)=CN(CC3=NC(C=CC(CI)=N4)=C4N3)C2=O | 50.0 | 12 | 4 | 1%HMC 0.5% Tween80 | Yes | 94.6% | 0.03 |
| OR BrC(C=C3)=CC1=C3N(CC(0)CN(C)C)C2=C1C=C(Br)C=C2 30.0 12 4 No NA Wiskostatin (MMV672987) OR CN(C)CC(CN1C2=C(C=C2)Br)C3=C1C=CC(=C3)Br)O 12 4 1% HPMC / 5% DMSO No Na | | OC(CN(C)C)CN1C2=CC=C(Br)C=C2C3=C1C=CC(Br)=C3 | | | | | | | |
| Wiskostatin (MMV672987) OR CN(C)CC(CN1C2=C(C=C2)Br)C3=C1C=CC(=C3)Br)O 1% HPMC / 5% DMSO | | OR BrC(C=C3)=CC1=C3N(CC(O)CN(C)C)C2=C1C=C(Br)C=C2 | 30.0 | 12 | 4 | | No | NA | |
| | Wiskostatin (MMV672987) | OR CN(C)CC(CN1C2=C(C=C(C=C2)Br)C3=C1C=CC(=C3)Br)O | | | | 1% HPMC / 5% DMSO | | | |

EC₉₀, indicates 90% C. parvum growth inhibitory concentration as measured in the regular 48 h assay (1) - citation Bessoff et al. 2013 AAC

HPMC, hydroxypropyl methyl cellulose

ND, not done

^a As determined by qPCR on fecal samples on the day after completing treatment.

Supplementary References:

- 1. Bessoff, K. et al. Identification of *Cryptosporidium parvum* active chemical series by Repurposing the open access malaria box. *Antimicrob Agents Chemother* **58**, 2731-9 (2014).
- 2. Chou, T.F. et al. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. *Proceedings of the National Academy of Sciences of the United States of America* **108**, 4834-9 (2011).
- 3. Palencia, A. et al. *Cryptosporidium* and *Toxoplasma* Parasites Are Inhibited by a Benzoxaborole Targeting Leucyl-tRNA Synthetase. *Antimicrob Agents Chemother* **60**, 5817-27 (2016).
- 5. Bessoff, K., Sateriale, A., Lee, K.K. & Huston, C.D. Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block *Cryptosporidium parvum* growth. *Antimicrob Agents Chemother* **57**, 1804-14 (2013).
- 6. Castellanos-Gonzalez, A. et al. A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis. *J Infect Dis* **208**, 1342-8 (2013).
- 7. Love, M.S. et al. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis. *PLoS Negl Trop Dis* **11**, e0005373 (2017).
- 8. Winzer, P. et al. In Vitro and In Vivo Effects of the Bumped Kinase Inhibitor 1294 in the Related Cyst-Forming Apicomplexans *Toxoplasma gondii* and *Neospora caninum*. *Antimicrob Agents Chemother* **59**, 6361-74 (2015).
- 9. Ojo, K.K. et al. *Neospora caninum* calcium-dependent protein kinase 1 is an effective drug target for neosporosis therapy. *PLoS One* **9**, e92929 (2014).
- 11. Lee, S. et al. Therapeutic Efficacy of Bumped Kinase Inhibitor 1369 in a Pig Model of Acute Diarrhea Caused by *Cryptosporidium hominis*. *Antimicrob Agents Chemother* **62**(2018).
- 13. Kato, N. et al. Diversity-oriented synthesis yields novel multistage antimalarial inhibitors. *Nature* **538**, 344-349 (2016).
- 14. Hoepfner, D. et al. Selective and specific inhibition of the *Plasmodium falciparum* lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin. *Cell Host Microbe* **11**, 654-63 (2012).
- 15. Jain, V. et al. Targeting Prolyl-tRNA Synthetase to Accelerate Drug Discovery against Malaria, Leishmaniasis, Toxoplasmosis, Cryptosporidiosis, and Coccidiosis. *Structure* **25**, 1495-1505 e6 (2017).
- 16. Hain, A.U. et al. Identification of an Atg8-Atg3 protein-protein interaction inhibitor from the medicines for Malaria Venture Malaria Box active in blood and liver stage *Plasmodium falciparum* parasites. *J Med Chem* **57**, 4521-31 (2014).
- 17. Varberg, J.M., LaFavers, K.A., Arrizabalaga, G. & Sullivan, W.J., Jr. Characterization of *Plasmodium* Atg3-Atg8 Interaction Inhibitors Identifies Novel Alternative Mechanisms of Action in *Toxoplasma gondii*. *Antimicrob Agents Chemother* **62**(2018).
- 18. Hoffman, P.S. et al. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of *Helicobacter pylori*, selected anaerobic bacteria and parasites, and *Campylobacter jejuni*. *Antimicrobial agents and chemotherapy* **51**, 868-76 (2007).
- 19. Bartelt, L.A. et al. Amixicile Reduces Severity of Cryptosporidiosis but Does Not Have In Vitro Activity against *Cryptosporidium*. *Antimicrob Agents Chemother* **62**(2018).
- 20. Morrissette, N.S., Mitra, A., Sept, D. & Sibley, L.D. Dinitroanilines bind alpha-tubulin to disrupt microtubules. *Mol Biol Cell* **15**, 1960-8 (2004).

- 21. Benbow, J.W., Bernberg, E.L., Korda, A. & Mead, J.R. Synthesis and evaluation of dinitroanilines for treatment of cryptosporidiosis. *Antimicrob Agents Chemother* **42**, 339-43 (1998).
- 22. Gorla, S.K. et al. Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis. *Antimicrob Agents Chemother* **58**, 1603-14 (2014).
- 23. Vinayak, S. et al. Genetic modification of the diarrhoeal pathogen *Cryptosporidium parvum*. *Nature* **523**, 477-80 (2015).
- 24. Jumani, R.S. et al. A novel piperazine-based drug lead for cryptosporidiosis from the Medicines for Malaria Venture open access Malaria Box. *Antimicrob Agents Chemother* **62**, e01505-01517 (2018).
- 25. Downey, A.S., Chong, C.R., Graczyk, T.K. & Sullivan, D.J. Efficacy of pyrvinium pamoate against *Cryptosporidium parvum* infection in vitro and in a neonatal mouse model. *Antimicrob Agents Chemother* **52**, 3106-12 (2008).
- 27. Shibata, S. et al. Selective inhibitors of methionyl-tRNA synthetase have potent activity against *Trypanosoma brucei* Infection in Mice. *Antimicrob Agents Chemother* **55**, 1982-9 (2011).
- 28. Chen, X.-M. et al. Cdc42 and the Actin-Related Protein/Neural Wiskott-Aldrich Syndrome Protein Network Mediate Cellular Invasion by *Cryptosporidium parvum*. *Infection and immunity* **72**, 3011-3021 (2004).